Navigation Links
Generation of a severe memory-deficit mutant mouse by exclusively eliminating the kinase activity of CaMKIIalpha
Date:6/19/2009

Ca2+/calmodulin-dependent protein kinase II alpha (CaMKII alpha) is an enzyme that adds phosphates to a variety of protein substrates to modify their functions. CaMKII alpha is enriched in the hippocampus, the memory center of the brain, and is believed to be an essential mediator of activity-dependent synaptic plasticity and memory functions. However, the causative role of the enzymatic activity of CaMKII alpha in such processes has not been demonstrated yet, because this enzyme has multiple protein functions other than the kinase activity. A Japanese research group, led by Dr Yoko Yamagata of the National Institute for Physiological Sciences, Japan, has successfully generated a novel kinase-dead mutant mouse of the CaMKII alpha gene that completely and exclusively lacks its kinase activity. They examined hippocampal synaptic plasticity and behavioral learning of the mouse, and found a severe deficit in both processes. They reported their findings in the Journal of Neuroscience, published on June 10, 2009.

The research group successfully generated a novel CaMKII alpha (K42R) knock-in mouse that completely lacks the kinase activity of CaMKII alpha, and examined the effects on structural, functional, and behavioral expression of synaptic memory. In the K42R brain, tetanus-induced long-term potentiation (LTP), a proposed cellular mechanism of memory, and sustained postsynaptic spine enlargement, a structural basis for LTP, were both impaired, whereas dynamic postsynaptic movement of CaMKII alpha protein was preserved. In addition, the K42R mouse showed a severe deficit in inhibitory avoidance learning, a form of memory dependent on the hippocampus. The research group concluded that the mutant mouse could not form memories and did not remember the events that had just happened.

"We demonstrated that the mutant mouse has a severe memory deficit because of the lack of the kinase activity of CaMKII alpha. This finding supports the idea that the kinase activity of CaMKII alpha is essential to memory functions. Such a memory-deficit mutant mouse could serve as an animal model to study the molecular mechanisms of memory, and be a useful tool for the development and screening of therapeutic reagents for memory-deficit disorders. It may also help open a new therapeutic approach to memory dysfunctions in patients.", said Dr Yamagata.


'/>"/>

Contact: Dr. Yoko Yamagata
yamagata@nips.ac.jp
81-564-595-887
National Institute for Physiological Sciences
Source:Eurekalert

Related medicine news :

1. Next Generation Waters - Nuu
2. Abbott Initiates Trial of Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Building Upon Superior Outcomes from SPIRIT Family of Trials
3. Abbott Announces Launch of Next-Generation Embolic Protection System
4. Purity Products Partners with Leading Vitamin D Expert to Create Next-Generation D3 Complex
5. San Francisco Symposium Provides Training for Communities Looking to Develop Arts Programs That Unite Generations
6. RainEarth Applies for Patent for Second Generation Blood Dialysis Equipment
7. Nonin Medical Introduces Next-Generation Regional Oximeter at Euroanaesthesia 2009
8. ZigBee Selected by Continua Health Alliance for Next Generation Guidelines
9. Compressus Delivers Imaging Productivity & Efficiency Improvements in Next Generation MEDxConnect(TM) Workflow Management Solution
10. First heart patients implanted with next-generation mechanical heart pump
11. AARP to Host Cross-Generational Life Festival in Chicago, June 5-6
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... Salt Lake City, Utah (PRWEB) , ... August 16, 2017 , ... ... its spot on the Inc 5000 list for the fourth consecutive year. ... the Inc. 5000 2017 list of the nation’s fastest growing companies. , ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... ... to patients suffering from chronic pelvic pain. In addition to oncology services, ... pain disorders including endometriosis, menorrhagia (abnormal heavy bleeding during menstruation), uterine fibroids, and ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... awards program which recognizes organizations that demonstrate the core values of business innovation, ... categories. , “As a global company, we are expanding our presence in all ...
(Date:8/16/2017)... ... , ... “Mom, God's Got This: Jamie's Story” is the creation of published author, Karen F. ... an insatiable appetite for God’s Word. , “I froze between the half walls, shelves on ... of oatmeal. I have one to this day on proud display in my dining room ...
(Date:8/15/2017)... ... ... city of Los Angeles is a west coast style fashion center as well as a ... website that spotlights fashion news from Los Angeles and around the world, is sharing clothing ... to the senior editor of latsl.com , “For a business that is known for ...
Breaking Medicine News(10 mins):
(Date:8/4/2017)... -- Agragen, LLC, a Cincinnati -based ... and aquacultural feed sectors, announces a significant step ... AGR131.  This drug is designed to trap and ... patients suffering from inflammatory conditions such as rheumatoid ... Biological pharmaceuticals currently used ...
(Date:8/2/2017)... BENTON, Ky. , Aug. 2, 2017   Marshall County Hospital in ... (ES) team to proactively reduce the risk of hospital-acquired infections (HAIs). The new addition, ... uses UVC light energy to kill deadly pathogens such as C. diff , MRSA, ... Tru-D SmartUVC ... Tru-D in action in a patient room ...
(Date:8/1/2017)... , Aug. 1, 2017   CerSci Therapeutics ... Dallas, Texas , has received notice from ... National Institutes of Health (NIH) that it has been ... grant totaling over $650,000 in 2017 with an additional ... CerSci,s Investigational New Drug application of their lead non-opioid ...
Breaking Medicine Technology: